Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab concentration-guided dose reduction versus standard dosing in rheumatoid arthritis
2025-520513-30-00Phase 4Authorised
- Sponsor
- Reade
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Reade. Primary endpoint: Mean time-weighted DAS28 at 28 weeks. Planned start Jan 2025; status: authorised.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2025-520513-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520513-30-00.